Oramed Pharmaceuticals Inc. — Director's Dealing 2017

Jul 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2017-06-30

Reporting Person: KIDRON NADAV (Director, President and CEO, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-30	Stock Option (right to buy)	$7.77	A	147000	Acquired	2027-06-30	Common Stock (147000)	Direct

Footnotes

F1: The Stock Option will vest in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the company share price reaching the target of $8.0, $9.5 and $12.5 per share, respectively.